e-SPACE Cardio-Renal-Metabolic 2023
Published: 25 March 2023
59m 17sPart 2 | Session 5 Plenary session 9 – Managing “metals”
1h 2m 16sPart 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
1h 3m 10sPart 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
1h 1m 47sPart 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
58m 8sPart 1 | Session 1 Plenary session 1 – HFpEF Andrew JS Coats, Giuseppe Rosano, Eberhard Standl, María José Soler, Stefan Anker
51m 57sPart 1 | Session 2 Satellite symposium – SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? (Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance) Stefan Anker, Paola Fioretto, Michel Jadoul
56m 38sPart 1 | Session 3 Plenary session 2 – SGLT2 updates Andrew JS Coats, Hiddo Lambers Heerspink, Antonio Ceriello, Gianluigi Savarese, Christoph Wanner
31m 38sPart 1 | Session 4 Meet the expert – Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys Ewa Jankowska, Andrew JS Coats
58m 54sPart 1 | Session 5 Plenary session 3 – Weight management in CRM disease Luc Van Gaal, Wolfram Doehner, Milton Packer, Carel le Roux, Tammy Lyn Kindel, Ildiko Lingvay
30m 11sPart 1 | Session 6 Meet the expert – Implementation patterns and challenges in HF care: insights from the EVOLUTION HF study (Supported by an educational grant from AstraZeneca) Orly Vardeny, Gianluigi Savarese
1h 6m 3sPart 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients Stephan Von Haehling, Mehriban Isgandar, Alexandre Mebazaa, Adriaan A Voors, Marat Fudim, Vijay Chopra
58m 41sPart 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease Javed Butler, Sunil Bhandari, Edgar V Lerma, Faiez Zannad, Janani Rangaswami, Gerasimos Filippatos
25m 15sPart 1 | Session 9 Meet the expert – Single pill combination (SPC) in Cardiorenal metabolic (CRM) disease Stefan Anker, Muthiah Vaduganathan
59m 5sPart 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches Nisha Bansal, Christopher Wilcox, Wilfried Mullens, Areef Ishani, William T Abraham
e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.
Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.
For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
John J Atherton
Director of Cardiology
Dr John Atherton is Director of Cardiology, Royal Brisbane and Women’s Hospital, Associate Professor, University of Queensland, and Adjunct Professor, Queensland University of Technology.
Dr Atherton was on the board of the Cardiac Society of Australia and New Zealand (CSANZ, 2009–2015) and chairs the CSANZ Professional Ethics Standards Committee. He previously chaired the Asia-Pacific Acute Decompensated Heart Failure Registry Scientific Advisory Committee and the CSANZ Heart Failure Council. Dr Atherton is an appointed member of the Australian Government Medical Services Advisory Committee and provides advice to Government on public funding arrangements through Medicare.
Dr Atherton is Associate Editor, Heart Lung and Circulation, and sits on the editorial board for Cardiac Failure Review. His research interests include screening for pre-symptomatic heart disease and heart failure disease management. His contributions to service enhancement…
Petar M Seferovic
Professor of Internal Medicine
Prof Petar Seferović is a Professor of Internal Medicine at Belgrade University, Belgrade, RS.
In 1990, he got his PhD from the School of Medicine, University of Belgrade.
Prof Seferović is the past President of the Heart failure Association of the ESC and has co-authored over 800 publications.
John GF Cleland
Professor of Cardiology
Prof John Cleland is a Professor of Cardiology at University of Glasgow, Glasgow, UK.
In 1977, he qualified from the University of Glasgow, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation.
His main interests include heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines.
He founded the European Journal of Heart Failure and is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure.
Director Internal Medicine Clinic III, Angiology and Intensive Care Medicine
Dr Michael Böhm performed his medical training at the Medical School of Hannover in Germany. Residency in Internal Medicine and fellowships in Cardiology at the Ludwig Maximilians-Unversity in Munich/Germany at the Klinikum Großhadern; Heisenberg Graduate of the Deutsche Forschungsgemeinschaft; Assistant and Associate Dr of Internal Medicine and Cardiology at the Universität zu Köln in Germany.
Dr Böhm is Director of the Klinik für Innere Medizin III and Chief of Cardiology at the University of the Saarland in Homburg/Saar in Germany. Dr Böhm's special interest includes pathophysiology and therapy of heart failure. Particular, he is involved in studies on signal transduction in the failing heart and in vascular biology. Dr Böhm has been the principal investigator in several international multicenter studies. He has written more than 350 original papers, book chapters and review articles. He has obtained several awards of scientific societies. Dr Böhm is a reviewer for…
Director of the NHMRC Clinical Trials Centre
Prof Meg Jardine is Director of the NHMRC Clinical Trials Centre at University of Sydney, Camperdown, AU.
She is a member of the International Society of Nephrology Executive Committee (2023 – 2025), an Executive Committee member of the international nephrology guidelines body, KDIGO, and has contributed to Australian CARI guideline development.
Prof Jardine's research focusses on reducing the progression and complications of non-communicable diseases, particularly kidney disease, diabetes and cardiovascular disease, through randomised trials and epidemiological analyses.
Daniël van Raalte
Professor of Medicine
Dr Daniël van Raalte is a Professor of Medicine at Amsterdam UMC, Amsterdam, NL.
His particular interest is in Clinical Diabetology and his top areas of expertise include Type 2 Diabetes (T2D), Diabetic Nephropathy, Wilson Disease, and Osmotic Diuresis.